Abstract. Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies. We have recently shown that some neuroblastoma cell lines are sensitive to direct cytotoxicity of the anti-GD2 mouse monoclonal antibody 14G2a (mAb). For IMR-32 and LA-N-1 cell lines, treatment with the 14G2a mAb induced evident changes in appearance such as cell rounding, aggregation, loose contact with culture plastic, or detachment. Such findings prompted us to investigate whether modulation of attachment of neuroblastoma cells to extracellular matrix (ECM) proteins can affect their sensitivity to the 14G2a mAb treatment. First, using ultra-low attachment plates, we show that survival of the IMR-32, LA-N-1, LA-N-5, CHP-134 and Kelly cells depends on attachment. Next, we compared cellular ATP levels of the cell lines treated with the 14G2a mAb using uncoated, fibronectin-, collagen IV-coated surfaces to show that the ECM proteins slightly modulate sensitivity of the cell lines to the mAb. Then, we characterized presence of selected integrin subunits or their complexes on the cell surface. Finally, we applied small molecule inhibitors of selected integrin complexes: obtustatin (inhibiting α1β1 heterodimer), BIO 1211 (inhibiting active α4β1 heterodimer), cilengitide and SB273005 (inhibitors of αVβ3, αVβ5 heterodimers) to verify their effects on attachment of cell lines, cellular ATP levels, and in some experiments activities of apoptosis-executing caspase-3 and -7, for the compounds used alone or in combination with the 14G2a mAb. We characterized levels of total FAK (focal adhesion kinase), p-FAK (Tyr397) in IMR-32 cells treated with BIO 1211, and in LA-N-5, Kelly and SK-N-SH cells treated with SB273005. Our results extend knowledge on factors influencing cytotoxicity of 14G2a.
Introduction
Neuroblastoma is a childhood malignancy arising from primitive neuroblasts of the sympathetic part of the peripheral nervous system. The disease is characterized by evident age dependence, which affects prevalence and prognosis (1) . Hence, neuroblastoma is the most common type of tumor diagnosed in infancy, and the majority of cases are diagnosed in patients up to 5 years of age (after http://www.cancer.org/ cancer/neuroblastoma/detailedguide/neuroblastoma-keystatistics).
More importantly, children above 18 months of age have poor prognosis for overall survival (2) . It should be stressed that heterogeneity is an intrinsic feature of neuroblastoma, despite limited landscape of genetic alterations (3) . Thus, on the one hand, the disease may spontaneously regress in some patients, but on the other hand in about half of patients advanced aggressive tumors are diagnosed, which demand intensive multiagent and multimodal treatment (4) . The fact that children with high risk neuroblastoma have poor prognosis fuels approaches to broaden treatment options for the group of patients.
GD2-ganglioside (GD2), a cell surface-exposed and sialic acid-containing glycosphingolipid, is a marker of neuroblastoma and a relevant target for anti-neuroblastoma immunotherapy with monoclonal antibodies (5) . Since 2015, the treatment options for high risk patients that at least partially responded to first line therapy were widened with FDA-approval of a chimeric human mouse monoclonal antibody dinutuximab (ch14.18) (6) . The antibody is used in line with 13-cis retinoic acid, IL-2 and GM-CSF to control minimal residual disease (7) . Other GD2-specific antibodies such as mouse monoclonal antibodies 14G2a (sharing
Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a
a paratope with ch14.18) or 3F8 either had been or are continuously being tested in clinics, respectively (5) . Several researchers have set goals to investigate mechanism of interactions of ganglioside-binding antibodies with cancer cells (reviewed in ref. 8) . It is evident that, in addition to involvement of antibodies in immune-based mechanisms of cancer eradication, direct cytotoxic effects may result from binding of antibodies to tumor cells. Such data, including ours, are also available for anti-GD2 ganglioside antibodies and neuroblastoma (9, 10) . Thus, we showed that some neuroblastoma cell lines are sensitive to direct cytotoxicity of the anti-GD2 antibody 14G2a (mAb). Furthermore, we have already reported an increase in p53, but a drop of MYCN in nuclear protein fractions, a decrease in Aurora A kinase, and downregulation of activity of the Akt/mTOR signaling network, which correlated with decreased cellular ATP levels in IMR-32 neuroblastoma cells after the mAb treatment (10, 11) . Also, we were able to show that 13-cis retinoic acid, Aurora A inhibitor MK-5108, a dual PI3K and mTOR inhibitor BEZ-235, when combined with 14G2a, can further decrease cellular ATP levels in some neuroblastoma cell lines (10, 11) . The data add to efforts to screen for new drug combinations to improve survival of cancer patients.
Integrins are a group of transmembrane proteins connecting cells to extracellular matrix of intercellular spaces and basement membranes, via binding to proteins such as fibronectin, collagens, laminin and vitronectin. The receptors are responsible for signal transduction regulated from cell outside, after ligand-induced activation of integrin complexes, and from cell inside, due to activity of specific protein complexes associating with cytoplasmic domains of integrins (12, 13) . In mammals, 24 heterodimeric complexes, differing in their ligand selectivity, can be formed utilizing one of 18 α and one of 8 β subunits (12) . In cancer cells, roles of specific integrin subunits or complexes in regulation of migration, survival, angiogenesis and metastasis are intensively studied (14) . Characterization of biological roles of integrins fuelled development and clinical trials of their antagonists, in the form of antibodies such as etaracizumab (15) , volociximab (16) , and inhibitors, e.g., cilengitide (17) . Some links between neuroblastoma phenotype and integrins have also been established. Thus, in 2015 Young et al (18) showed that integrin α4 may be correlated with poor outcome of neuroblastoma patients diagnosed with tumors without MYCN amplification and possibly allows for their further classification. Also, Lee et al (19) showed that overexpression of gastrin-releasing peptide in neuroblastoma increases expression of integrins α2, α3, β1 and used siRNA to show that integrin β1 was necessary for SK-N-SH migration. Additionally, links between tumor cell attachment, integrins and gangliosides are one of the areas of research. Cheresh et al (20) reported that M21 human melanoma cells are detached from fibronectin-coated wells by the anti-GD3 ganglioside (GD3) MB3.6 mAb. Ohkawa et al (21) found that GD3-positive melanoma cells exhibited stronger adhesion to collagen I and collagen IV, as compared to GD3-negative counterparts. They also showed that β1 integrin and GD3 co-localized at points of focal adhesion.
One of the features often observed in cells cultures treated with ganglioside binding antibodies are changes in their morphology, i.e., more rounded appearance, aggregation, loose surface adherence, or detachment. Thus, Dippold et al (22) reported such changes in a panel of melanoma cell lines treated with the anti-GD3 mouse R-24 mAb. Cochonneau et al (9) showed morphology changes of IMR-5 cells treated with the anti-O-acetyl GD2 8B6 and the anti-GD2 10B8 mAbs. We noted such features in IMR-32 and LA-N-1 neuroblastoma cell cultured with the anti-GD2 14G2a mAb (10, 23) . Also, we showed that 14G2a in a dose-dependent manner interferes with attachment of IMR-32 cells to fibronectin (23) . Therefore, we applied selective inhibitors of integrin complexes α1β1 (obtustatin) (24) , α4β1 (BIO 1211) (25) and αVβ3/αVβ5 [cilengitide (26), SB273005 (27) ] to seek answers whether inhibition of integrin binding to extracellular matrix proteins affects sensitivity of neuroblastoma cells to treatment with the anti-GD2 14G2a mAb.
Based on our previous results, we used five GD2-positive neuroblastoma cell lines with varying sensitivity to the 14G2a mAb (10), i.e., IMR-32, LA-N-1, LA-N-5, CHP-134, Kelly and GD2-negative SK-N-SH cells to characterize expression of some integrin subunits and complexes. Also, we measured effects of the aforementioned inhibitors on cell attachment and survival. Finally, as our goal was to broaden knowledge on factors affecting cytotoxicity of the 14G2a mAb against neuroblastoma cell lines, we report effects of the inhibitors and the 14G2a mAb, used as single agents or combined, on attachment and cell survival.
Materials and methods
Cell culture of neuroblastoma cell lines. In our experiments, we used six human neuroblastoma cell lines obtained from cell collections, i.e., IMR-32 (ATTC, LCG Standards, Lomianki, Poland; cat no. CCL-127), LA-N-1 (ECACC, Sigma-Aldrich, Poznan, Poland; cat. no. 06041201), CHP-134 (ECACC, cat. no. 06122002), LA-N-5 (cat. no. ACC 673; Leibniz-Institut DSMZDeutsche Sammlung von Mikroorganismen und Zellkulturen GmbH), Kelly (cat. no. ACC 355; DSMZ) and SK-N-SH (cat. no. ATCC HTB11). Cells were cultured in 5% CO 2 atmosphere in media as previously described in detail (10) .
Anti-GD2 ganglioside antibody purification. The hybridoma cell line producing the 14G2a mAb, which is a mouse IgG2a that binds to GD2, was kindly provided by Dr R.A. Reisfeld (Scripps Research Institute, La Jolla, CA, USA). Cell culture and the antibody purification from fetal bovine serum (FBS) free-cell culture supernatant using HiTrap™ Protein G columns (cat. no. 17-0404-03; GE Healthcare Bio-Sciences AB, Uppsala, Sweden) were previously described in detail (10) .
Detection of integrins expressed on neuroblastoma cell lines with a cell adhesion array. Analyses of integrin content of cells were performed with Alpha/Beta Integrin-Mediated Cell Adhesion Array Combo kit (cat. no. ECM532; Chemicon International, Merck Sp. z o.o., Warszawa, Poland) with protocol optimized based on the manufacturer's suggestions. Prior to the tests, neuroblastoma cells were detached from culture plastic vessels with 2 mM EDTA in phosphate-buffered saline (PBS, cat. no. PBS404.2; BioShop ® Canada, Lab Empire, Rzeszów, Poland), at room temperature and then centrifuged (for 10 min, at 4˚C, at 315 x g). The cell pellets were resuspended in assay buffer provided by the kit manufacturer and cells were counted using the trypan blue exclusion method. Between 0.1x10 6 and 0.2x10 6 of cells in 100 µl of assay buffer (depending on the cell line tested) were added per well, followed by incubation for 2 h at 37˚C in an incubator with 5% of CO 2 . Single wells with antibodies binding respective integrin subunits or complexes (also single negative control wells, NC) were used per experiment. Then, the cells were processed according to the manufacturer's instructions. Signals of absorbance at 560 nm were collected with an Infinite M200 reader (Tecan Schweiz AG, Männedorf, Switzerland). To normalize signals between experiments, we calculated ratios between signals from wells coated with, respective, anti-integrin antibodies and signals of negative control wells (NC). Two experiments are shown for IMR-32, CHP-134, LA-N-5, Kelly (marked as ex-1, ex-2 in Fig. 4 ). One experiment was performed for LA-N-1 cells.
Flow cytometry. Cells were detached using 2 mM EDTA in PBS at room temperature, and 2% FBS in PBS (FBS, cat. no. 10270-106; Life Technologies, Warszawa, Poland) was used for cell staining and washing. Following antibodies were applied: the 14G2a mAb for GD2 staining, while PK136 mAb (mouse IgG2a) (10) Treatment of cells with the 14G2a mAb, the peptides and the inhibitors of integrins. Prior to the tests, neuroblastoma cells were detached from culture plastic with 2 mM EDTA in PBS, at room temperature, and then centrifuged (for 10 min, at 4˚C, at 139 x g). The cell pellets were resuspended in respective complete media and counted using the trypan blue exclusion method. The seeding density for IMR-32 and LA-N-1 was 2x10 4 cells/100 µl/well and for CHP-134, LA-N-5, Kelly, SK-N-SH was 5x10 3 cells/100 µl/well. For 14G2a-treatment of cells, the antibodies in PBS were added (control samples were treated with PBS alone when necessary). All samples with cells were incubated on ice for 1 h with mixing after every 15 min of incubation, before transfer of 100 µl to wells of respective plates.
Where appropriate, inhibitors (see above) were added to cells, after incubation with the 14G2a mAb (controls treated with solvents of inhibitors were included where necessary). Obtustatin was tested at the concentrations of 0.012, 0.06, 0.3 and 1.5 µM; BIO 1211 was tested at the concentrations of 1, 2.5 and 5 µM; cilengitide was tested at the concentrations of 3 and 10 µM; and SB273005 was tested at the concentrations 0.3, 1, 3, 10 and 30 µM.
For testing of effects of #94-12-F/W-AAEGD or scrambled control peptides on cytotoxicity of the 14G2a mAb, the seeding density for IMR-32 and CHP-134 cell lines was 2x10 4 cells/100 µl/well to better fit microscopic examinations. The peptides were added to cells after incubation with antibodies on ice (from 10 mM stock solution) to the final concentrations of 0.23 or 0.114 mM. Separate controls cells (when necessary) were also treated with peptides, and/or diluent of peptides, and/or PBS (diluent for 14G2a) to check for any effects on cellular ATP levels.
After the above treatments, cells were incubated for 72 h at 37˚C in an incubator with 5% of CO 2 . On the third day of incubation microscopic pictures were taken of some cell cultures using the Leica microscope DM IL LED Fluo equipped with the DFC450C camera, using 10x-(506263, HI PLAN I, 10x/0.22) or x20-magnification objectives (506264, HI PLAN I, 20x/0.30) and collected using the Leica Application Suite Version 4.3.0 (Leica Microsystems GMBH, Wetzlar, Germany). Cellular survival (based on measurements of ATP levels) or caspase-3/-7 activities were determined as described below.
For attachment assays, the seeding density for all cell lines was 2x10 4 cells/100 µl/well. Cells were treated with integrin inhibitors, 14G2a, or their combinations (see above), and then incubated for 2 h at 37˚C in an incubator with 5% of CO 2 . Control cells treated with diluents were included (were necessary). Next, unattached cells were removed by inversion of plates, while the remaining cells were analyzed using cellular ATP measurements (see below). For western blot analysis, LA-N-5, Kelly and SK-N-SH cells were treated with 3 µM SB273005 for 6 and 24 h, IMR-32 cells were treated with 5 µM BIO 1211 for 6 and 24 h. Control cells were treated with diluents.
Measurements of viable cell number through determination of levels of ATP and analysis of apoptosis through determination of caspase-3/-7 activities in cell cultures.
We used an ATP assay as a sensitive method to estimate viable cell number in attachment experiments, and to determine effects of tested agents (the 14G2a mAb, the peptides and the integrin inhibitors) on neuroblastoma cell viability (proliferation and cytotoxicity). Cellular ATP contents were analyzed using ATPlite, luminescence ATP detection assay system (cat. no. 6016947; Perkin-Elmer, Warszawa, Poland) based on the protocol of the manufacturer to measure cell survival in experiments. For measurements of activities of apoptosis-executing caspase-3/-7, we used Caspase-Glo ® 3/7 assay (cat. no. G8091; Promega) according to the manufacturer's protocol. Where necessary, equal volumes of cell lysates were transferred to white plates and luminescence signals were collected using the Infinite M200 reader.
Western blot analysis. Cells were collected using trypsin-EDTA (cat. no. T3924; Sigma-Aldrich) and centrifuged for 5 min (2,500 x g at 4˚C). Cell pellets were washed twice with ice-cold PBS (with centrifugation steps to recover cells as pellet). Next, cells were lysed with gentle mixing by inversion (for 45 min, at 4˚C) using buffer containing: 25 mM Tris-HCl (pH 7.6, cat. no. TRS001.1; BioShop), 10 mM NaCl (cat. no. 794121116; Avantor Performance Materials Poland S.A., POCH, Gliwice, Poland), 1% NP-40 (cat. no. NON999.500; BioShop), 1% sodium deoxycholate (cat. no. D6570; SigmaAldrich), 0.1% SDS (cat. no. L4390; Sigma-Aldrich), Halt Phosphatase Inhibitor Cocktail (cat. no. 78420; Thermo Fisher Scientific, ALAB Laboratoria, Warszawa, Poland), and Complete Protease Inhibitor Cocktail (cat. no. 11697498001; Roche, Warszawa, Poland). Then, samples were centrifuged 14,000 x g, at 4˚C, for 15 min. Samples were resolved using SDS-PAGE (12% gels) as described in detail (10) . Western blot analyses were performed with application of the following antibodies (all from Cell Signaling Technology-Lab-JOT Ltd., Warszawa, Poland): anti-FAK (cat. no. 13009, dilution 1:1,00), anti-phospho-FAK (Tyr397) (cat. no. 8556, dilution 1:1,000), anti-α-tubulin (cat. no. 2125, dilution 1,000-2,000), anti-rabbit IgG, HRP-linked antibody (cat. no. 7074, 1:2,000). Chemiluminescent signals were developed with the Immobilon Western HRP Substrate (cat. no. WBKLS0500; Millipore, Warszawa, Poland) and collected using the MicroChemi System (DNR Bio Imaging Systems, ALAB Laboratoria, Warszawa, Poland).
Statistical analyses. Multivariate analysis was performed with one-way repeated measures ANOVA with a GreenhouseGeisser correction. Then, we performed post hoc pairwise comparisons by Dunnett's test at the significance levels set at 0.05, 0.01, 0.001 were applicable. In multivariate analyses data were analyzed without normalization (30) . Data shown on graphs were normalized to control set as 1 for clarity. Data on graphs (except for Fig. 4 ) are presented as means of experiments (n, numbers of experiments performed were from 2 to 5, performed in duplicate, triplicate or quadruplicate, as described in the figure legends) ± SEM (a standard error of the mean). Data in Table II 
Results
A peptide mimicking GD2 ganglioside blocks cytotoxic effects of 14G2a mAb. Phage-displayed peptide libraries can be screened with monoclonal antibodies with various specificities and yield mimicking peptides binding to the screening molecules and inhibiting interactions with the cognate antigens. Previously, we reported optimization and characterization of binding to the 14G2a mAb of cyclic peptides mimicking GD2 ganglioside (28, 29) . In the present study, we show that peptide #94-12F/W-AAEGD (RCNPNMEPPRCWAAEGD, marked as GD2 MIMIC in Fig. 1 ), used at the concentration 0.23 mM (also 0.114 mM concentration; data not shown), can abolish the cytotoxic effects of the 14G2a mAb as compared to the control scrambled sequence (marked as SCR PEPTIDE, NPERCNRWMPCPAEADG). IMR-32 and CHP-134 cells grown in the presence of the 14G2a mAb exhibited morphological changes such as cell aggregation. The effects were abolished by the GD2 MIMIC (Fig. 1A , images taken 72 h after incubation). Also, for both cell lines, the ATP levels in the presence of the GD2 MIMIC and the 14G2a mAb were statistically significantly higher than in cells treated with the SCR PEPTIDE and the mAb ( Fig. 1B ; GD2 MIMIC + 14G2a vs. SCR PEPTIDE + 14G2a by Dunnett's test with the significance level set at 0.001; and Fig. 1C , GD2 MIMIC + 14G2a vs. SCR PEPTIDE + 14G2a by Dunnett's test with the significance level set at 0.05). There was no statistically significant difference between ATP cell levels in samples treated with 14G2a or 14G2a and SCR peptide (Dunnett's test), thus, the scrambled control peptide did not affect sensitivity of cells to the mAb. Moreover, there was no statistically significant difference between cells treated with SCR PEPTIDE and GD2 MIMIC (Dunnett's test). Therefore, the fact that the GD2 mimicking peptide, but not the control sequence, eliminated the cytotoxic effects of 14G2a confirms that the observed effects rely on binding of the mAb to GD2 ganglioside. In our previous study, we used the PK136 mAb as a negative control (10) . Hence, the data obtained with the peptide provide additional evidence that the cytotoxic effects of 14G2a are specific and require binding between GD2 and 14G2a.
Survival of the neuroblastoma cell lines is dependent on attachment.
We have previously published data showing that selected neuroblastoma cell lines are sensitive to direct cytotoxicity of the anti-GD2 antibody 14G2a mAb (10, 23) . Thus, we measured that cellular ATP levels decreased in time-and dose-dependent manner in cultures of some neuroblastoma cells treated with the mAb (10). Additionally, for IMR-32 and LA-N-1 cell lines treatment with the mAb induced clear changes in appearance such as cell rounding, aggregation, detachment (10) (Fig. 2) . For other cells, such as LA-N-5 and CHP-134 the changes were less pronounced (10) (Fig. 2) . Kelly cells did not exhibit easily visible changes in their morphology and were only to a limited extent sensitive to the mAb treatment (10) (Fig. 2) .
The above findings prompted us to hypothesize that modulation of attachment of cells may influence sensitivity of neuroblastoma cell lines to 14G2a. Hence, we used IMR-32, LA-N-1, LA-N-5, CHP-134 and Kelly neuroblastoma cell lines, as they are highly GD2-positive (Table I shows GD2 analyses on IMR-32, LA-N-5, CHP-134 and Kelly cells) and are to various extent sensitive to the antibody (10) . We compared effects of attachment on survival of neuroblastoma cell lines, also in the presence of the mAb 14G2a (used in the concentration of 20 µg/ml). First, we used ultra-low binding plates (non-adherent conditions) and standard cell culture plates (adherent conditions) to compare effects of such culture plastic vessels on cell morphology by microscopic observation and cell survival by measurements of cellular ATP. We report that all tested cell lines formed large aggregates on non-adherent plates (Fig. 2, right panel) .
Also, we compared levels of cellular ATP in cultures after 72 h of incubation, with or without treatment with the mAb, on both types of plates (normalized to control cells treated with PBS and grown in adherent conditions, set as 1; Fig. 3A-E) . We report a statistically significant decrease in cellular ATP of cell cultures grown on non-adherent plates as compared to standard culture plates. Thus, the measured values were from 0.62±0.03 (for Kelly cells) to 0.75±0.045 (for LA-N-5 cells) of the values of cells grown on the standard plates (P<0.05 for CHP-134, LA-N-1, LA-N-5; P<0.01 for IMR-32 and Kelly). For the cells treated with 14G2a (for the great majority of the tests), we measured lower ATP levels in cultures grown on nonadherent surfaces as compared to standard plates (Fig. 3A-E) . Out of five cell lines tested, for CHP-134 cells the ATP levels decreased approximately by additional 10% on non-adherent plates and were statistically meaningful for the 20 µg/ml concentrations of the 14G2a mAb (P<0.05). For Kelly cells, the levels of ATP were statistically significantly lower for the 20 µg/ml concentration of the 14G2a mAb used (P<0.01; Fig. 3E ). For IMR-32, LA-N-1 and LA-N-5 cells the results of 14G2a treatment obtained compared between adherent and non-adherent conditions in the presence of the 14G2a mAb were not statistically meaningful.
Previously, we reported that treatment with the mAb caused a rise in caspase-3/-7 activities in IMR-32 cells after 24 and 48 h of treatment (10) . Here, we provide more data, showing that culturing of the IMR-32 cells for 72 h on non-adherent plates resulted in an increase of activities of caspase-3/-7 ~20%, but without statistical significance. However, for both adherent and non-adherent plates in the presence of 14G2a (20 µg/ml), the increase of activities of caspase-3/-7 was ~60 and 70%, respectively (Fig. 3F , when compared to control cells treated with PBS grown in adherent conditions, set as 1). Also, for CHP-134, LA-N-1 and LA-N-5 the highest activities of caspase-3/-7 were measured for cells cultured on low-binding plates and in the presence of the 14G2a mAb (20 µg/ml), when compared to other conditions tested, but the data did not reach statistical significance due to variation between experiments (Fig. 3G-I) .
Characterization of selected integrins on the cell surface of neuroblastoma cell lines.
We made an attempt to preliminary characterize presence of integrins on IMR-32, CHP-134, LA-N-1, LA-N-5 and Kelly cell lines with application of an α/β integrin-mediated cell adhesion array that uses antibody-coated wells to retain cells expressing given integrin chains or their complexes (Fig. 4 , data from two experiments are shown, marked as ex-1 and ex-2 on the graphs). For the analyses, we assumed that a relative signal >2 is a positive sign that a given integrin subunit or complex is present on cells. For IMR-32 and CHP-134 cells clear signals of binding of α1, α4 and β1 chains were measured. Additionally, on CHP-134 cells α2 and α3 subunits were detected. On LA-N-5 cells α1, α2, and β1 but no α4 were detected. Also, for CHP-134, LA-N-5 signals of binding to αV, αVβ3 and αVβ5 were measured. For Kelly cells due to high background measured in wells of controls it is hard to draw unequivocal conclusions, hence the line was included in the further tests (described below). Also for LA-N-1 cells, in one experiment, we measured positive signals from α1, α2, α4, αV and β1 (data not shown). Further testing was performed using flow cytometry (Table II shows percentage of positively stained cells in the analyzed pools). We showed that in concordance with the aforementioned array, β1 integrin was expressed on majority of IMR-32, CHP-134, LA-N-5 and Kelly cells. Furthermore, α4 chain was unequivocally present in pools of analyzed IMR-32 cells (i.e., on ~30% cells). On CHP-134 and Kelly cells, expression of α4 chain was detectable, yet restricted only to small percentage of cells (i.e., ~3% of CHP-134 cells and ~6.5% of Kelly cells). Lack of αVβ3 ranged approximately from 2 to 6%, and for αVβ5 from 2.5 to 15% (data not shown). This suggests need for further characterization of levels of integrins and relationships between their expression and cell culture conditions (such as cell time in culture, culture cell density, or specific cell banks used). Additionally, we included GD2-negative SK-N-SH cells to the analyses ( Table I ) and showed that α4, β1 chains and αVβ3, αVβ3 complexes are present in majority of the analyzed cells (Table II) . Hence, the cell line was included in some research described in following chapters.
Characterization of sensitivity of neuroblastoma cell lines to treatment with the 14G2a mAb on surfaces coated with fibronectin and collagen IV.
The above data prompted us to investigate effects of extracellular matrix proteins, i.e., fibronectin, collagen IV on changes of ATP levels induced after treatment of cells with the 14G2a mAb.
We compared cellular ATP levels of cells cultured on fibronectin-and collagen IV-coated wells to control cells grown on standard cell culture plates, after treatment with the mAb in the concentrations of 20 µg/ml (PBS treated cells were also included). The effects were subtle; hence we calculated data as means ± SEM from three experiments (data not shown). For IMR-32, CHP-134 and LA-N-1 cells, we observed an increase in levels of cellular ATP on plates coated with fibronectin or collagen IV, when compared to cells grown on uncoated plates. However, the statistically meaningful increases in ATP levels (~10%) were measured only for the LA-N-1 cells treated with 14G2a and cultured on collagen IV plates (P<0.05). The smallest changes (and without statistical significance) were measured for CHP-134 cells. Thus, we find that interaction of neuroblastoma cells with the ECM proteins can lead to lower sensitivity of some cell lines to the mAb treatment.
Effects of inhibitors of α1β1 and α4β1 integrin complexes on appearance, attachment, survival of neuroblastoma cell lines
and their sensitivity to 14G2a mAb. We decided to use two inhibitors of integrin complexes α1β1 or α4β1, i.e., obtustatin or BIO 1211, to test their effects on IMR-32, CHP-134 and Kelly cells. The inhibitors were tested alone and in combination with the 14G2a mAb (20 µg/ml) on plates coated with collagen IV or fibronectin, respectively.
Obtustatin used in the concentrations 0.012, 0.06, 0.3 and 1.5 µM did not affect ATP levels of IMR-32, CHP-134, Kelly cells (data not shown). Moreover, no change in sensitivity to treatment with 14G2a was observed when the inhibitor (applied in the above mentioned concentrations) was combined with 20 µg/ml of 14G2a (after 72 h of treatment; data not shown). This is in line with the observations that the inhibitor did not induce changes of the cell morphology and attachment of the three lines, when investigated on the third day of culture by microscopic observation. Some cell rounding was observed 2 h after obtustatin (e.g., 1.5 µM) addition to IMR-32 cells (data not shown).
BIO 1211 used in the concentrations 1, 2.5 and 5 µM affected appearance of IMR-32 cells, as visible after 72 h of culture, especially for 2.5 and 5 µM BIO 1211 (Fig. 5A for (Fig. 5C) -F(1.424, 2 .848)=27.359, P<0.015; (Fig. 5E) -F (1.015, 2 .030)=9.371, P>0.09; (Fig. 5G) -F(1.379, 2.757 further pairwise tests were not conducted (Fig. 5B and data not  shown) . For IMR-32, when mean values from three experiments were compared, the 14G2a mAb (20 µg/ml) reduced signal to 0.7±0.06, 5 µM BIO 1211 reduced signal to 0.62±0.1, and both agents reduced signal to 0.43±0.1 of control cells set as 1 (Fig. 5B) . For Kelly cells, the 14G2a mAb (20 µg/ml) did not affect attachment, 5 µM BIO 1211 reduced signal to 0.93±0.4, and both agents reduced signal to 0.89±0.04, when compared to control cells (set as 1, data not shown). For CHP-134 cells, the 14G2a mAb (20 µg/ml) and 5 µM BIO 1211 did reduce signals, and both agents reduced signal to 0.86±0.05, when compared to control cells (set as 1, data not shown). Also after 72 h of culture, the inhibitor reduced cellular ATP levels of the IMR-32 cells to 0.9±0.02 (of control cells treated with diluent, set as 1), 0.84±0.03 (of control) and 0.86±0.04 (of control); when used at the concentrations of 1, 2.5 and 5 µM, respectively (Fig. 5C) .
When compared to IMR-32 cells treated with mAb alone, lower levels of ATP were observed for cells treated with combinations of 1, 2.5 and 5 µM of BIO 1211 and 20 µg/ml of 14G2a (after 72 h of treatment), i.e., 0.45±0.03 (of control cells treated with diluent); 0.42±0.02 (of control cells treated with diluent); 0.44±0.03 (of control cells treated with diluent); respectively, yet the values did not reach statistical significance when compared to signals from samples treated only with 14G2a by Dunnett's test (Fig. 5D , also data not shown). For CHP-134 and Kelly cells treated with BIO 1211 in the concentrations 1, 2.5 and 5 µM the reduction levels were either not observed (e.g., CHP-134 cells treated with 1 µM) or <10% (Fig. 5C) . No additional statistically meaningful effects were observed when the 14G2a mAb (1 or 2.5 or 5 µM) and 14G2a (20 µg/ml) were used alone or the inhibitor and the mAb were used in combinations, multivariate analyses did not yield statistically significant P-values (data not shown). As a result, further pairwise tests were not conducted. Using western blot analysis, we showed that 5 µM BIO 1211, added for 6 and 24 h to IMR-32 cells, did not change levels of p-FAK (Tyr397) and total FAK (Fig. 5E) .
Effects of inhibitors of αVβ3 and αVβ5 integrin complexes on appearance, attachment, survival of neuroblastoma cell lines and their sensitivity to the 14G2a mAb. We decided to use two inhibitors of integrin complexes αVβ3 or αVβ5, i.e., cilengitide (CGT) or SB273005 (SB), to test their effects on LA-N-5, CHP-134 and Kelly cells. The inhibitors were tested alone and in combination with the 14G2a mAb (20 µg/ml) on plates coated with vitronectin.
In cell cultures grown on vitronectin (VN), SB37005 (Fig. 6 ) and cilengitide (data not shown) induced changes: in shape (in Kelly cells), cell spreading (of CHP-134 cells), and aggregation (of LA-N-5 cells). Aggregation was evident for LA-N-5 cells, but for Kelly cells the cell rounding was quite subtle. CHP-134 cells tend to cover vitronectin-coated surface more evenly without SB273005 suggesting that their migration may be affected by it. Effects were observed for 3 and 10 µM concentrations of both inhibitors (Fig. 6 and data not shown) . Microscopic observations have been extended with attachment assays on vitronectin-coated wells. First, we report that vitronectin-coated wells retained more cells, ~80% more for LA-N-5, ~40% more for Kelly, and approximately 30% more for CHP-134, as compared to control, BSA blocked wells (after 2 h of incubation, P<0.01 for LA-N-5, by two sample t-test, data not shown). Moreover, 3 and 10 µM SB273005 used alone or in combination with 14G2a statistically meaningfully reduced attachment of LA-N-5, CHP-134 (as compared to controls set as 1, Fig. 7C and G) after 2 h of incubation. For Kelly cells, the inhibitor used alone or combined with 14G2a reduced cell attachment by ~40% (Fig. 7E) . However, multivariate analysis did not yield statistically significant P-values (data not shown). As a result, further pairwise tests were not conducted.
Also, we tested SB273005 on uncoated plates in the range of concentrations from 0.3 to 30 µM. GD2-negative SK-N-SH cells known from the literature to express αV (19) and from our cytometry data to express αVβ3 and αVβ5 were also included (Table II) . When ATP levels were measured 72 h after addition of the inhibitor to cell cultures grown on standard uncoated wells, for SK-N-SH a clear cytotoxic effect was observed, as the cells were decimated for all conditions tested (Fig. 7A) . The ATP levels of SH-N-SH dropped by ~70% (Dunnett's test with the significance level set at 0.001, as compared to control cells). In case of LA-N-5 cells, the ATP levels decreased ~15% (but no significant P-value was obtained from multivariate analysis). For Kelly, ATP levels decreased <10% (with statistical significance by Dunnett's test; Fig. 7A ). No effects on cellular ATP levels were observed for CHP-134 incubated with SB273005 for 72 h. Additionally, we analyzed levels of phosphorylated FAK, pFAK (Tyr397), and total FAK in SK-N-SH, LA-N-5 and Kelly treated with 3 µM SB273005 for 6 and 24 h (Fig. 7B, D and F) . No changes of levels of total FAK were observed. A clear drop in the level of phosphorylated FAK (Tyr397) was observed in SK-N-SH cell treated with the inhibitor for 24 h (Fig. 7B ), which correlates with high toxicity of the inhibitor against the cell line.
Clear changes in cellular appearance, i.e., cell rounding, partial or complete aggregation and detachment, were observed for CHP-134, LA-N-1 and Kelly when cilengitide or SB273305 (10 and 3 µM) were combined with the 14G2a mAb (for 72 h, data not shown). Importantly the combination of cilengitide or SB273005 (10 and 3 µM) and 14G2a (20 µg/ml) resulted in lower ATP levels, when compared to cells treated with the single drug, although the effects were rather small, possibly due to restricted expression of αVβ3 in cultures of CHP-134, LA-N-5, Kelly cells, and αVβ5 in cultures of CHP-134, LA-N-5 ( Fig. 8 and Table II) . For all cells effects of 14G2a where statistically significant when compared to control cells (Dunnett's test, not marked on Fig. 8 ). For LA-N-5 the effects of the mAb were statistically significantly potentiated by 3 and 10 µM SB273005 (Fig. 8D , Dunnett's test) and for Kelly for 3 µM cilengitide and 10 µM SB273005 (Fig. 8E and F, Dunnett's test) . Also, SB273005 increased caspase-3/-7 activities in CHP-134, LA-N-5, Kelly cells (Fig. 9) , and the effects were statistically meaningful for the last two cell lines mentioned ( Fig. 9B and C; Dunnett's  test) . Importantly, for LA-N-5 and Kelly cells, the effects of the mAb were statistically significantly potentiated by 3 and 10 µM SB273005 (Fig. 9B and C (18) showed that integrin α4 may be associated with poor outcome in neuroblastoma patients without MYCN amplification. Hsu et al (34) reported that expression of the B4GALNT3 protein in tumor samples correlated with good outcome. More importantly, the authors showed that levels of the protein increased in SK-N-SH cells by all-trans retinoic acid-treatment. Also, they showed that B4GALNT3 expression suppressed cell migration and invasion along with downregulation of β1 signaling (34) . Furthermore, Leblond et al (35) showed expression of αVβ3 and αVβ5 on some neuroblastoma cell lines along with their sensitivity to cilengitide.
The results presented by us stemmed from our observation that in cell lines such as IMR-32, LA-N-1 and CHP-134, the treatment with the anti-GD2 14G2a mAb was accompanied by changes in cellular morphology (10) (Fig. 2) . Additionally, we found that the nonadherent surface used for culture of all tested neuroblastoma cell lines led to decreased ATP levels. On the contrary, presence of fibronectin or collagen IV in wells where IMR-32 and LA-N-1 cells were treated with the 14G2a mAb, led to increased values of cellular ATP. The above data encouraged us to investigate how selected inhibitors of integrins influenced cell sensitivity to 14G2a. Also, our report on the integrin expression on IMR-32, CHP-134, LA-N-1, LA-N-5, Kelly and SK-N-SH cells add to already published data and allowed us to plan experiments with the inhibitors used.
Based on the findings, we decided to take advantage of selective inhibitors of integrin complexes: obtustatin (inhibitor of α1β1), BIO 1211 (inhibitor of active α4β1), cilengitide and SB273005 (inhibitors of αVβ3, αVβ5) that were used alone or in combination with the 14G2a mAb in our experiments. Our data showed that cellular ATP levels of IMR-32, CHP-134 and Kelly cells grown on collagen IV were not affected by obtustatin in the concentrations tested, with or without the 14G2a mAb. Effects of BIO 1211 on cellular appearance and ATP levels were evident only for IMR-32 cells grown on fibronectin, possibly due to very restricted expression of α4 subunit in CHP-134 and Kelly cell cultures. No data on expression of α4β1 on the cell lines was obtained, due to the fact that no commercially available antibody specific for the human integrin complex was found. Due to limited expression of α4 and possibly of α4β1, multivariate analyses showed no significant differences of viability between cells treated with the 14G2a mAb and combination of BIO 1211 and the mAb. Future experiments should be planned on integrin-enriched pools of cells to characterize sensitivity of neuroblastoma cells positive for α4β1, αVβ3 and αVβ5 to inhibitors and the 14G2 mAb, as α4 was shown to be linked to outcome in neuroblastoma (18) and the αVβ3 complex contributes to cancer stem cells, and along with α4β1 to bone metastasis (31) . To gather more information, our future experiments should include testing other concentrations of the inhibitors. Also, testing for caspase-3/-7 activation in treated cell lines in additional time-points, such as 24 or 48 h, to find if there is time-dependence in our models. Effects of our drugs on caspase-8 activity can be tested (if expressed), as unligated or antagonized integrins promote caspase-8 activation (36) . Furthermore, the data could be extended with experiments investigating how the 14G2a mAb (alone or in combination with the integrin antagonists) affect neuroblastoma migration and invasion. In that context, it would be interesting to characterize if expression and localization of integrins is affected by the 14G2a in neuroblastoma. It is already established that treatment of some neuroblastoma cell lines with all-trans retinoic acid and fenretinide decreased levels of β1 integrin (37) . Combination of the inhibitors could also be used, as from the evidence of expression of several integrins in the cell lines and known overlap of their ligand specificities redundancy effects may be expected. It should be noted that a dual antagonist of α1β1/α2β1 integrins was recently reported (38) . Also, other proteins, i.e., galectins affecting integrin clustering, can be inhibited in our models (39).
Wu et al (33) reported that migration of NB8 neuroblastoma cells mediated by α5β1 integrin involved pathways engaging SRC and FAK, but movement mediated by α4β1 integrin involved only SRC. We have already shown that dephosphorylation of β-catenin (phosphorylation of the protein is involved in anoikis resistance) (40) , Tyr397 of FAK (the phosphorylation is important for cell survival) (41) , an increase in activating phosphorylation of Tyr420 of FYN (expression of active FYN is linked to good outcome in neuroblastoma independently of MYCN amplification) (42) , downregulation of AKT/mTOR network, a decrease in nuclear levels of MYCN (a known regulator of FAK expression) (43) are all linked among other changes of proteins to treatment of IMR-32 with 14G2a (10, 11) . From the available literature, it is known that targeting kinases linked to integrin signaling can be exploited in neuroblastoma therapy. Therefore, a small molecule inhibitor of FAK affects neuroblastoma cell growth in vitro and in vivo, with greatest effects observed for cells with higher MYCN levels (41) . Also, FAK/PAK1/MAPK cascade is linked to promotion of anchorage-independent growth by integrin β1 in breast cancer cells (44) . Thus, our data encourage for further characterization of signaling pathways involving integrins, also in neuroblastoma cells treated with integrin inhibitors, used alone or in combination with the 14G2a mAb. Again, in this context, neuroblastoma cell populations enriched for α4, αVβ3 and αVβ5 integrins should be used.
Finally, although our goals were focused on application of the inhibitors to verify involvement of their targets in sensitivity of selected cell lines to the 14G2a mAb, additional aspects of such drug combinations could be examined using in vivo models of neuroblastoma. This include testing of potential of tumor cells to metastasize to sites characteristic for high risk neuroblastoma such as bones or lymph nodes, in the presence of 14G2a and inhibitors of integrins, used alone and in combinations, possibly with neuroblastoma cell populations enriched for α4, αVβ3 and αVβ5 integrins. Such experiments could yield clinically relevant data. Effects on tumor growth, angiogenesis and immune system should be carefully evaluated, especially as the recent findings show that cilengitide failed to improve survival in glioblastoma in clinical trials (17) . Also, Su et al (45) reported that targeting integrin β3 with cilengitide increased immunosuppression in cancer models.
To summarize, we applied small molecule inhibitors of selected integrin complexes: obtustatin (inhibiting α1β1), BIO 1211 (inhibiting active α4β1), cilengitide and SB273005 (inhibitors of αVβ3, αVβ5) and verified their effects on appearance, attachment and survival of neuroblastoma cell lines, for the compounds used alone or in combination with the mAb. Our results broaden knowledge on factors influencing cytotoxicity against neuroblastoma cell lines evoked by 14G2a.
